# Gland Pharma Limited - Inspection Records

Source: https://www.keypedia.com/companies/gland-pharma-limited/dd730d79-1c97-4fb0-b717-c0ebd71a5b3f

> Inspection records and compliance data for Gland Pharma Limited in Hyderabad, None. Access full analysis and detailed observations.

---

## Details

- Name: Gland Pharma Limited
- FEI Number: 3002647489
- City: Hyderabad
- State: None
- Country Name: 500043 India
- Address Line 1: Survey 143-148
- Address Line 2: 150-151 Gandimaisamma, Cross Road, D P Pally, Quthubullapur Medchal-Malkajgiri District
- Zip Code: None
- Business Operations: API MANUFACTURE, API/FDF ANALYTICAL TESTING, FDF MANUFACTURE, PACK

## Related Documents

- [EIR - Gland Pharma Limited - 2025-08-25](https://www.keypedia.com/records/eir/gland-pharma-limited/782a11ea-4dcf-4e82-beb1-39459e334adf) — source: FDA, date: August 25, 2025
- [483 - Gland Pharma Limited - 2024-07-25](https://www.keypedia.com/records/483/gland-pharma-limited/a1d0389a-8f1b-419e-aa72-90e50dbc4369) — source: FDA, date: July 25, 2024
- [483 - Gland Pharma Limited - 2024-07-25](https://www.keypedia.com/records/483/gland-pharma-limited/56cd5b1f-5d10-4fea-b13f-c9d3d980f6d4) — source: FDA, date: July 25, 2024
- [FDA Inspection 1244548 - Gland Pharma Limited - 2024-07-25](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/acffcfce-62b6-4883-95ee-555ed8943c50) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 25, 2024
- [483 - Gland Pharma Limited - 2023-07-14](https://www.keypedia.com/records/483/gland-pharma-limited/a8b23a0b-1439-46db-b7a7-ac096d7940c7) — source: FDA, date: July 14, 2023
- [FDA Inspection 1210381 - Gland Pharma Limited - 2023-07-14](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/a827d7e0-fc10-4952-baf6-b295d8269dbc) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 14, 2023
- [483 - Gland Pharma Limited - 2022-08-25](https://www.keypedia.com/records/483/gland-pharma-limited/cbd5ee58-0d35-4dc8-a3c5-c1f424b4f63a) — source: FDA, date: August 25, 2022
- [FDA Inspection 1179407 - Gland Pharma Limited - 2022-08-25](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/d25b4f34-1b29-4a94-be87-9f1e6e0cceab) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 25, 2022
- [483 - Gland Pharma Limited - 2019-05-16](https://www.keypedia.com/records/483/gland-pharma-limited/4fa4ef18-c157-4399-965f-8e1c149ad245) — source: FDA, date: May 16, 2019
- [FDA Inspection 1090548 - Gland Pharma Limited - 2019-05-16](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/826a0fc9-eaf4-4d9e-9236-b51098beb6ed) — classification: Voluntary Action Indicated (VAI), source: FDA, date: May 16, 2019
- [483 - Gland Pharma Limited - 2017-02-03](https://www.keypedia.com/records/483/gland-pharma-limited/4c06b549-e8e1-48c8-9a60-71c5ade7f2dc) — source: FDA, date: February 3, 2017
- [FDA Inspection 1002974 - Gland Pharma Limited - 2017-02-03](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/2790d68f-af89-4d25-a23e-b35acfa506d3) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 3, 2017
- [483 - Gland Pharma Limited - 2015-03-17](https://www.keypedia.com/records/483/gland-pharma-limited/e76b5f6e-2c1e-45b0-9c0e-e037a8f686a1) — source: FDA, date: March 17, 2015
- [FDA Inspection 921536 - Gland Pharma Limited - 2015-03-17](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/b47d8672-6428-41fd-bb87-db9406b20fe4) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 17, 2015
- [FDA Inspection 800507 - Gland Pharma Limited - 2012-09-07](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/27cbae17-083a-4568-bd1b-227cef709e39) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 7, 2012
- [FDA Inspection 709986 - Gland Pharma Limited - 2011-01-07](https://www.keypedia.com/records/fda_inspections/gland-pharma-limited/6d537451-5936-499e-a5f2-e02a22f2cc91) — classification: No Action Indicated (NAI), source: FDA, date: January 7, 2011

## Related Companies

- [Juno Therapeutics, Inc.](https://www.keypedia.com/companies/juno-therapeutics-inc/d564709e-29d0-4aaf-9d68-efbf3cd67a35)
- [Bavarian Nordic Berna GmbH](https://www.keypedia.com/companies/bavarian-nordic-berna-gmbh/c041bdf1-c3d5-46c3-a216-02ad314f45e0)
- [Henogen SRL](https://www.keypedia.com/companies/henogen-srl/273669c2-3349-41d3-a904-a56d90f76482)
- [Novartis Manufacturing LLC](https://www.keypedia.com/companies/novartis-manufacturing-llc/c4165663-ccb2-4abd-bba3-af6a0bdf462d)
- [Adaptimmune LLC](https://www.keypedia.com/companies/adaptimmune-llc/6394510c-b8e5-4662-a4f9-e3f788e5adcb)
- [Patheon Biologics Australia Pty Ltd](https://www.keypedia.com/companies/patheon-biologics-australia-pty-ltd/ede6b641-a0a7-4b0b-918b-f09c3b1d060b)
- [Pharmaron (Ningbo) Technology Development Co., Ltd.](https://www.keypedia.com/companies/pharmaron-ningbo-technology-development-co-ltd/c40334bd-b474-48eb-91c6-51a228da2a42)
- [STgen Bio Co., Ltd.](https://www.keypedia.com/companies/stgen-bio-co-ltd/bf0530c2-b747-4fce-ade6-52850415aac3)
- [Celltrion Inc.](https://www.keypedia.com/companies/celltrion-inc/d3991ec8-423b-4554-9d67-72bc27a8658b)
- [Minaris Regenerative Medicine, LLC](https://www.keypedia.com/companies/minaris-regenerative-medicine-llc/b5fdb186-e2e7-416c-b89e-66d15dbf5509)

## Related Officers

- [Senior Consumer Safety Officer](https://www.keypedia.com/people/carla-j-lundi/a10ed698-54fe-4635-a766-8c31f501dfb2)
- [Ademola O. Daramola](https://www.keypedia.com/people/ademola-o-daramola/814113a4-38bc-4ce5-b6af-09c7e688c0ec)
- [Katherine D Adams](https://www.keypedia.com/people/katherine-d-adams/8520bed2-00c9-4f75-bf91-d92b14b58d3d)
- [Investigator](https://www.keypedia.com/people/michael-a-charles/f83241f0-ae3b-4535-ac03-e790bbf666ca)